Variant ActRIIB Polypeptide for Post-Capillary Pulmonary Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a high unmet need for effective therapies to treat post-capillary pulmonary hypertension (PcPH), particularly in reducing its progression rate and severity, as current treatments mainly focus on addressing underlying conditions rather than directly targeting the pulmonary hypertension.
Innovation Solution
Administration of a variant ActRIIB polypeptide with specific amino acid sequences and substitutions, which is at least 75% to 100% identical to a reference sequence, to target complications such as smooth muscle and endothelial cell proliferation, angiogenesis, and pulmonary vascular remodeling, thereby reducing mean pulmonary arterial pressure and other associated symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments focus on addressing underlying conditions (e.g., heart failure, valvular disease), then the underlying disease is treated, but pulmonary hypertension progression is not directly addressed
Solution Approach 1:
The patent extracts and targets the specific pathogenic role of activin A in pulmonary hypertension by using an activin A antibody that selectively binds to activin A. This allows direct intervention in the PH pathway independent of the underlying condition, separating PH treatment from general heart failure treatment.
Solution Approach 2:
The activin A antibody serves as an intermediary substance that mediates between the underlying heart failure condition and the pulmonary hypertension. It blocks the harmful effect of activin A on pulmonary vessels while allowing the underlying condition to be managed separately by its own treatments.
2Object-affected harmful factors
If activin A signaling is blocked to reduce pulmonary vascular remodeling, then PH severity is reduced, but other activin A functions may be affected
Solution Approach 1:
The patent applies local quality by designing an activin A antibody with specific binding characteristics that target activin A's harmful effects on pulmonary vessels while preserving its beneficial functions in other tissues. The antibody's affinity and tissue distribution are optimized to achieve selective action.
Solution Approach 2:
The patent utilizes parameter changes by modifying the antibody's binding parameters (affinity, specificity) to differentiate between activin A's harmful and beneficial effects. By adjusting these parameters, the treatment selectively blocks pulmonary vascular remodeling while maintaining other activin A functions.
3Stress or pressure
If mean pulmonary arterial pressure is reduced, then PH symptoms improve, but the mechanism to achieve this is not well understood
Solution Approach 1:
The patent implements feedback by monitoring changes in mean pulmonary arterial pressure and other PH parameters in response to activin A blocking. This feedback information is used to optimize the antibody dosing and timing to achieve maximum pressure reduction while minimizing side effects.
Solution Approach 2:
The patent applies preliminary action by administering the activin A antibody before significant pulmonary vascular remodeling occurs. This preventive approach reduces the development of PH symptoms and maintains lower mean pulmonary arterial pressure over time, rather than treating established severe PH.
Data Source
AI summary
In some aspects, the disclosure relates to compositions and methods comprising variant ActRIIB polypeptides or heteromultimers thereof to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.